MSF Access

We advocate for access to & development of lifesaving medicines, tests & vaccines for people in MSF programmes & beyond. #MedicinesShouldntBeALuxury

[MSF International @MSF]

How does conflict amplify antimicrobial resistance?

🔴 Higher chance of infection as stress and malnutrition weaken immune systems
🔴 Spread of resistant bacteria due to overcrowding in displacement camps
🔴 Destruction of health facilities

https://t.co/ztD0hxKY15

[MSF International @MSF]

Post-rape kits. Contraceptives. Maternal care.

Women and girls lost sexual and reproductive health services in 2025, as funding cuts and politicisation jeopardised safe and dignified care ⬇️

https://t.co/YIZOhbybx4

[MSF Access @MSF_access]

Read the full statement: https://t.co/wFDWKroKbU

[MSF Access @MSF_access]

Today at the Open Plenary of the Fair Pricing Forum, Kris Torgeson, Executive Director of MSF Access, delivered a strong message on how to overcome affordability and transparency barriers. Here are the four key points she made.
👇

[MSF Access @MSF_access]

“Working in partnership with communities is essential for building trust and ensuring meaningful participation in the development of vaccines that are effective, adapted, and accessible to those who need them most,” Bern-Thomas Nyang'wa, Medical Director, MSF, highlighted.

[MSF Access @MSF_access]

💉First participant vaccinated in Tumaini!

Tumaini, a pivotal Phase 2/3 vaccine trial for the Bundibugyo virus causing #Ebola, will work closely with affected communities, health authorities and outbreak response partners to generate robust evidence.

[MSF Access @MSF_access]

“The inclusion of pregnant women and children represents an important step towards generating evidence for populations that are often excluded from clinical trials,” Valérie Briand, Head of the Research Department, Epicentre, said.

https://t.co/hezTBRMCbs

[MSF Access @MSF_access]

The ongoing Bundibugyo #Ebola virus (BDBV) outbreak has highlighted significant challenges in controlling transmission.

With currently no specific vaccine licensed against BDBV, we examined four vaccine candidates through an access lens: https://t.co/igas4f3AjB

[MSF Access @MSF_access]

Rupa Narra is an MSF pediatrician who recently worked at an #Ebola treatment center in North Kivu, Democratic Republic of Congo, where she witnessed a harsh reality for children facing a disproportionately high risk of death.

[MSF Access @MSF_access]

Children cannot continue to wait.

“Treatments, vaccines, and other preventive tools should be evaluated for use in children from the outset of research efforts and made available to them without delay,” says Dr Manangama, epidemiologist and deputy director of operations at MSF.

[MSF International @MSF]

Children are being left behind in the research of innovative medical tools for the current Ebola disease outbreak in DRC.

Children are also disproportionately impacted by the outbreak, with the youngest facing the highest risk of death.
https://t.co/ql8busz02M

[MSF Access @MSF_access]

MSF has been closely following the PABS negotiations since the start, actively sharing our position advocating for a strong, equitable and effective PABS system: https://t.co/wVjHl54spX

[MSF Access @MSF_access]

MSF welcomes the adoption of the UN Political declaration on pandemic prevention, preparedness and response. It reinforces global solidarity and provides political momentum for ongoing negotiations on WHO-led Pandemic Agreement Annex on Pathogen Access and Benefit Sharing System.

[MSF International @MSF]

Our programmes in Malawi and Mali contribute to showing that it is possible to diagnose, prevent, and treat cancer in fragile and humanitarian settings.

We’re speaking at the World Cancer Conference this week to share our experience:
https://t.co/uM46SxvNKx

[MSF Access @MSF_access]

“Funders, researchers and policymakers engaged in therapeutics' clinical trials must act now to include the right access conditions in a transparent way,” said Dr Monica Rull, MSF Access

[MSF Access @MSF_access]

MSF published a technical brief analysing access challenges concerning three Bundibugyo Ebola Virus therapeutic candidates - MBP134, remdesivir, and obeldesivir.

https://t.co/XZt652IqkL

[MSF Access @MSF_access]

Publicly available information on pricing, licensing, supply, and post-trial access remains very limited despite repeated calls for transparency.

[MSF Access @MSF_access]

Médecins Sans Frontières (MSF)/Doctors Without Borders is pleased to announce @KrisTorgeson as the new Executive Director of MSF Access.

https://t.co/5Hlf8iGWDo

[MSF Access @MSF_access]

In a commentary published in The Lancet today, MSF calls for urgent action to ensure children are included in Bundibugyo research on treatment and prevention and have timely access to paediatric formulations for oral post-exposure prophylaxis trials.

https://t.co/wnV4t7yEgU

[MSF Access @MSF_access]

What is the global double standard in #diabetes care? Authors from Voices in Action Diabetes outline the issue and explore possible solutions: https://t.co/MDHqgomlLY

[MSF International @MSF]

💢 Antimicrobial resistance brings added dangers to communities during conflict.

Read on to learn more 👇
https://t.co/ztD0hxKY15